IXC

2.86%

7.2¢ invex therapeutics ltd

Ann: Invex Granted European Orphan Drug Designation for TBI, page-63

First 63 Last

Share
Profile

Follow
BalkanBroker

1,386 Posts.

281

25/06/23

23:13

Post #: 68461912
Share

Originally posted by arkangel256: ↑

Correct. Tropical Diseases is a special case for which PRV apply for adults.

To get technical - if we're talking about Priority Review Vouchers here, then Reon1 is correct in stating that a reformulation will not get a Priority Review Voucher. This is because the active ingredient needs to be unique. Neuren's trofinetide is an example.

However, Invex is not seeking to exploit Priority Review Vouchers. It is going down a completely different pathway. It is utilising the Orphan Drug Designation pathway for which reformulation and repurposing is within scope. There is no stipulation preventing one drug from earning more than one orphan drug approval.

It is unlikely that Invex will seek to simply re-use Presendin in TBI. The active ingredient is a synthetic form of Exendin-4, for which Invex bought the rights from Astrazeneca for neurological indications. They reformulated this to 'Presendin' to match the disease characteristics of the IIH condition.

Invex will likely undergo a proof of concept study(Phase 2) for TBI, for which the final reformulation they will seek to get approval for will be different to Presendin for IIH, as they will need to use a reformulation with a different pharmacokinetic profile to be effective in TBI. We know in 2020, Invex raised capital post Phase II results, for a proof of study in a 2nd indication. Three years later, we finally know that it is for Traumatic Brain Injury, for which they're funded to complete.

Invex's strategy is simple. Achieve success in the Phase 3 for IIH. Have a pipeline of proof of concept studies in other indications e.g. TBI. And then sell to Big Pharma who will pay several multiples for the next big blockbuster drug.

Expand

The last paragraph in this post is all you need to know. Plain and simple. It has been the game plan since day dot.

IXC Price at posting: 60.0¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

ASN

Utah authorities sign off on Anson's lithium extraction plans at Green River

ENV

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

VUL

Vulcan appoints investment bank and M&A veteran to board

MLS

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

MKG

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

MM8

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

AZY

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

NAM

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

There are more pages in this discussion • 12 more messages in this thread...

First 63 Last

Add IXC (ASX) to my watchlist

(20min delay)
Last 7.2¢		Change 0.002(2.86%)		Mkt cap ! $5.411M

Open	High	Low	Value	Volume
7.2¢	7.2¢	7.2¢	$1.701K	23.62K

Buyers (Bids)

No.	Vol.	Price($)
2	76375	7.2¢

Sellers (Offers)

Price($)	Vol.	No.
8.0¢	5000	1

View Market Depth

No.	Vol.	Price($)
2	76375	0.072
1	52915	0.070
1	84879	0.067
1	100000	0.066
1	50000	0.065

Price($)	Vol.	No.
0.080	5000	1
0.085	8805	1
0.090	126146	1
0.095	100000	1
0.100	8505	2

Last trade - 15.42pm 13/09/2024 (20 minute delay)

IXC (ASX) Chart

Ann: Invex Granted European Orphan Drug Designation for TBI, page-63

Utah authorities sign off on Anson's lithium extraction plans at Green River

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Vulcan appoints investment bank and M&A veteran to board

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Invex Granted European Orphan Drug Designation for TBI, page-63

Top Stories

Utah authorities sign off on Anson's lithium extraction plans at Green River

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Vulcan appoints investment bank and M&A veteran to board

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News